|
|
???tair.name??? >
???browser.page.title.author???
|
"zhu v w"???jsp.browse.items-by-author.description???
Showing items 1-6 of 6 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 臺大學術典藏 |
2022-09-15T01:08:53Z |
An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor–Refractory ALK-Positive or ROS1-Positive NSCLC
|
Zhu V.W.; Lin Y.-T.; Kim D.-W.; Loong H.H.; Nagasaka M.; To H.; Ang Y.L.-E.; Ock C.-Y.; Tchekmedyian N.; Ou S.-H.I.; Syn N.L.; Reungwetwattana T.; Chia-Chi Lin; Soo R.A. |
| 臺大學術典藏 |
2022-09-15T01:08:47Z |
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study
|
Subbiah V.; Hu M.I.; Wirth L.J.; Schuler M.; Mansfield A.S.; Curigliano G.; Brose M.S.; Zhu V.W.; Leboulleux S.; Bowles D.W.; Baik C.S.; Adkins D.; Keam B.; Matos I.; Garralda E.; Gainor J.F.; Lopes G.; Chia-Chi Lin; Godbert Y.; Sarker D.; Miller S.G.; Clifford C.; Zhang H.; Turner C.D.; Taylor M.H. |
| 臺大學術典藏 |
2022-08-10T02:37:37Z |
Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial
|
Lu S.; Wang Q.; Zhang G.; Dong X.; Yang C.-T.; Song Y.; Chang G.-C.; Lu Y.; Pan H.; Chiu C.-H.; Wang Z.; Feng J.; Zhou J.; Xu X.; Guo R.; Chen J.; Yang H.; Chen Y.; Yu Z.; Shiah H.-S.; Wang C.-C.; Yang N.; Fang J.; Wang P.; Wang K.; Hu Y.; He J.; Shi J.; Chen S.; Wu Q.; Sun C.; Li C.; Wei H.; Cheng Y.; Su W.-C.; Hsia T.-C.; Cui J.; Sun Y.; Ou S.-H.I.; Zhu V.W.; CHIH-HSIN YANG |
| 國立成功大學 |
2022 |
Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
|
Wang, M.;Yang, J.C.-H.;Mitchell, P.L.;Fang, J.;Camidge, D.R.;Nian, W.;Chiu, Chiu C.-H.;Zhou, J.;Zhao, Y.;Su, W.-C.;Yang, T.-Y.;Zhu, V.W.;Millward, Millward M.;Fan, Y.;Huang, W.-T.;Cheng, Y.;Jiang, L.;Brungs, D.;Bazhenova, L.;Lee, C.K.;Gao, B.;Xu, Y.;Hsu, W.-H.;Zheng, L.;J�nne, P.A. |
| 國立成功大學 |
2022 |
Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial
|
Lu, S.;Wang, Q.;Zhang, G.;Dong, X.;Yang, C.-T.;Song, Y.;Chang, G.-C.;Lu, Y.;Pan, H.;Chiu, Chiu C.-H.;Wang, Z.;Feng, J.;Zhou, J.;Xu, Xu X.;Guo, R.;Chen, J.;Yang, H.;Chen, Y.;Yu, Z.;Shiah, H.-S.;Wang, C.-C.;Yang, N.;Fang, J.;Wang, P.;Wang, K.;Hu, Y.;He, J.;Wang, Z.;Shi, J.;Chen, S.;Wu, Q.;Sun, C.;Li, C.;Wei, H.;Cheng, Y.;Su, W.-C.;Hsia, T.-C.;Cui, J.;Sun, Y.;Ou, S.-H.I.;Zhu, V.W.;Chih-Hsin, Yang J. |
| 臺大學術典藏 |
2021-11-03T02:33:00Z |
Clinicopathologic Features and Response to Therapy of NRG1 Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry
|
Drilon A.; Duruisseaux M.; Han J.-Y.; Ito M.; Falcon C.; Yang S.-R.; Murciano-Goroff Y.R.; Chen H.; Okada M.; Molina M.A.; Wislez M.; Brun P.; Dupont C.; Branden E.; Rossi G.; Schrock A.; Ali S.; Gounant V.; Magne F.; Blum T.G.; Schram A.M.; Monnet I.; JIN-YUAN SHIH; Sabari J.; P?rol M.; Zhu V.W.; Nagasaka M.; Doebele R.; Camidge D.R.; Arcila M.; Ou S.-H.I.; Moro-Sibilot D.; Rosell R.; Muscarella L.A.; Liu S.V.; Cadranel J. |
Showing items 1-6 of 6 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
